What Polyamyna does

Polyamyna Nanotech Inc. is a Canadian biotechnology company (founded 2017–2019, headquartered in St. John's, Newfoundland and Labrador) that develops nanotechnology-based antimicrobial solutions targeting drug-resistant pathogens and healthcare-associated infections (HAIs). It operates a portfolio of three core technologies: Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual antimicrobial effect and a proprietary electrostatic molecular-arm mechanism; MicroDome®, a registered-trademark antimicrobial additive engineered for integration into polymer matrices (PLA, nylon, polypropylene, thermoplastics, and 3D printing); and PRP-2019, an adjuvant antibiotic platform designed to restore efficacy of existing antibiotics against multi-drug-resistant bacteria without directly killing them. Supporting modules in earlier stages include antimicrobial fabrics, antifouling marine coatings, anti-MIC coatings for defense/aerospace, and a point-of-care diagnostic device for AMR pathogens. An R&D subsidiary was established in Chennai, India in 2021 at Ticel Biopark II.

The company's revenue model is structured around product sales of Keep Klear coatings to healthcare facilities, plus licensing/royalty arrangements for MicroDome (sold or licensed to polymer manufacturers) and potentially PRP-2019 (to pharmaceutical partners). Target verticals span hospitals and long-term care facilities, medical device manufacturers, polymer/OEM manufacturers, defense and aerospace, and marine/offshore infrastructure. GTM combines direct enterprise field sales into healthcare accounts with OEM/embedded integration partnerships for its polymer additive.

Polyamyna remains primarily pre-commercial. Its main activity to date is clinical validation: integration trials with Newfoundland & Labrador Health Services (NLHS) and a human factors study with W21C in Calgary, alongside the Health Canada PMRA approval process for Keep Klear targeted for Q4 2025. Total disclosed funding is approximately $2.26M USD-equivalent across a Genesis pre-seed, 2019 government grants (NL Government, NRC IRAP), 2020 SDTC funding, a 2023 NL Department of Industry non-dilutive grant, and a 2023 SEC Form D debt-to-equity conversion. No institutional VC/PE participation is disclosed.

Name

Polyamyna

Legal name

Polyamyna Nanotech Inc.

Website

https://polyamyna.ca

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Polyamyna Nanotech is a Canadian biotechnology company developing nanotechnology-based antimicrobial coatings (Keep Klear™), polymer-integrated antimicrobial additives (MicroDome®), and antibiotic adjuvant therapeutics (PRP-2019) to combat drug-resistant pathogens and healthcare-associated infections for hospitals, OEMs, defense, and marine markets.

Ownership category

akta.pro rank

Product category

Antimicrobial Coatings & Infection Prevention Technologies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)

SIC

Biological Products, (No Disgnostic Substances) (2836), Miscellaneous Chemical Products (2890), Miscellaneous Plastics Products (3080)

akta.pro primary industry

Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

akta.pro secondary industries

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Antimicrobial coatings
• Antimicrobial additives
• Antibiotic adjuvants
• Infection prevention
• Drug resistance therapeutics

Headquarters

HQ city

St. John's

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Keep Klear Microbicidal Coatings: Sale of continuously active antimicrobial coating products for healthcare facility surfaces. Revenue derived from product sales to hospitals and healthcare systems with demonstrated residual activity lasting up to 7 days per application.
2. MicroDome Antimicrobial Additive: Licensing and sale of antimicrobial additive technology to polymer manufacturers for integration into their products. Targets healthcare, aerospace, defense, and consumer goods manufacturers.
3. PRP-2019 Adjuvant Therapeutics: Antibiotic adjuvant compounds for co-administration with existing antibiotics to combat drug-resistant bacteria. Potential licensing to pharmaceutical companies or development as standalone therapeutic products.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Polyamyna develops and sells nanotechnology-based antimicrobial products that combat multi-drug-resistant pathogens and healthcare-associated infections. Its core offerings include Keep Klear™, a continuously active transparent microbicidal coating with a 7-day residual effect for healthcare facility surfaces; MicroDome®, an antimicrobial additive for integration into polymer matrices used in manufacturing; and PRP-2019, an antibiotic adjuvant platform that restores efficacy of existing antibiotics against drug-resistant bacteria. Customers include hospitals, healthcare systems, polymer manufacturers, and defense/aerospace integrators.

Product overview

Polyamyna Nanotech Inc. is a biotechnology company offering a portfolio of antimicrobial technologies. The core offerings include Keep Klear™ (a continuously active microbicidal coating with 7-day residual effect), MicroDome® (an antimicrobial additive for polymer integration), and PRP-2019 (an adjuvant antibiotic technology platform). Additional modules include antimicrobial fabrics, antifouling technologies for marine applications, Anti-MIC technologies for defense and aerospace, and a point-of-care diagnostic device for AMR pathogens (in development). These products work together to address infection prevention across healthcare, industrial, and defense settings.

Differentiator

Problem solved

Functional benefit

Brands

• Keep Klear™: Continuously active transparent microbicidal coating technology offering a 7-day residual effect for infection control in healthcare settings.
• MicroDome®
• PRP-2019

Products and services

• Keep Klear™ Continuously active transparent microbicidal coating technology offering a 7-day residual antimicrobial effect for healthcare surfaces. It eliminates up to 99.99% of infection-causing bacteria, viruses, fungi, and Human Coronavirus, and over 97% of spores and 99.9% of biofilms on coated surfaces; dries in under 10 minutes, withstands rigorous medical cleaning protocols, and is non-toxic and non-corrosive.
• MicroDome® Next-generation antimicrobial additive engineered for seamless integration into various polymer matrices (PLA, nylon, polypropylene, and other thermoplastics, including additive manufacturing/3D printing feedstocks), enabling manufacturers to produce antimicrobial-enhanced products without changing existing processes. Compliant with PMRA's Treated Articles criteria.
• PRP-2019 Adjuvant antibiotic technology platform that optimizes inactive commercial antibiotics for infectious diseases by boosting effectiveness against drug-resistant bacteria. Works synergistically with multiple antibiotic classes (demonstrated with Erythromycin against multi-drug-resistant E. coli in Galleria mellonella infection models) without directly killing bacteria, minimizing selection pressure and resistance development.
• Antimicrobial Fabrics Fabrics integrated with Polyamyna's antimicrobial technologies for use in healthcare facilities, public spaces, and consumer products; inhibit growth of clinically relevant drug-resistant pathogens while maintaining durability and wash resistance.
• Antifouling Technologies Advanced chemistry coatings that prevent accumulation of biofouling organisms on underwater surfaces such as ship hulls and marine infrastructure to enhance operational efficiency and reduce maintenance costs.
• Anti-MIC Technologies Antimicrobial coatings tailored for defense and aerospace applications, protecting critical surfaces from microbial contamination and microbially induced corrosion (MIC) in extreme environments.

Quantifiable outcome

• Eliminates >99% of MRSA within 15 minutes of contact on coated surfaces
• +6 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Newfoundland & Labrador Health Services (NLHS)coreStrategic or Co-development Partner · 1 January 2023Clinical trial partner for evaluating Keep Klear's effectiveness against multidrug-resistant pathogens in patient-facing post-surgical medicine wards. Part of a 2023 non-dilutive government-funded initiative to demonstrate product efficacy in real healthcare settings.
• W21C Research InstitutecoreStrategic or Co-development PartnerPartnership with W21C in Calgary focused on human factors trial to refine the Keep Klear commercialization offering through evaluation of the product's innovation journey.
• University of ManitobacoreStrategic or Co-development PartnerAcademic partnership for research collaboration in antimicrobial technologies and antibiotic discovery. Dr. Kishan Gorityala served as Research Associate and Dr. George Zhanel serves as Professor and Associate Head in Department of Medical Microbiology and Infectious Diseases.
• Canadian Antimicrobial Resistance Alliance (CARA)coreStrategic or Co-development PartnerAdvisory partnership with CARA, led by Dr. George Zhanel as Research Director. CARA is dedicated to combatting antimicrobial resistance and provides expert guidance on Polyamyna's research and development direction.
• US Environmental Protection Agency (US-EPA)minorOthersEngaged with US-EPA regarding regulatory process for claiming residual activity. Successfully passed maximum residual claim requirements for supplemental coatings.
• Health CanadaminorOthersHealth Canada Pest Management Regulatory Agency (PMRA) accepted residual claims for supplemental coatings. Keep Klear PMRA application filed in 2021 with approval target Q4 2025.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• AkzoNobel: Global paints and coatings company with antimicrobial coating product lines for healthcare, marine, and industrial markets. Competes with Keep Klear in healthcare coatings, with marine antifouling in the marine vertical, and has the scale to out-resource Polyamyna in enterprise sales.
• Troy Corporation: US specialty chemicals company with a broad portfolio of industrial biocides, antimicrobial additives, and preservatives. Competes with MicroDome in polymer/additive markets and with Keep Klear in surface antimicrobial applications at the industrial chemistry level.
• Lonza Group: Swiss global leader in microbial control solutions, biocide active ingredients, and contract manufacturing for pharma and biotech. Competes with MicroDome at the additive/formulation level and overlaps with PRP-2019 on the antimicrobial-therapeutics side.
• Microban International: Largest pure-play antimicrobial additives company globally, with technology integrated into thousands of consumer and industrial products. Competes head-to-head with MicroDome in polymer additives and also has surface-coating product lines overlapping with Keep Klear.

Direct peers

• Biointeractions: UK-based medical device coatings company specializing in antimicrobial, antithrombogenic, and biocompatible coatings. Direct peer to Polyamyna in antimicrobial coatings for medical devices and healthcare surfaces.
• Covalon Technologies: Canadian (Mississauga, Ontario) medical device coatings company developing antimicrobial silver-based technologies for catheters, wound dressings, and surface applications. Comparable to Polyamyna in size, geography, antimicrobial-coating focus, and healthcare customer orientation.
• BioCote: UK-based antimicrobial additive technology company that integrates silver-ion and similar additives into polymers, plastics, coatings, and textiles for healthcare and consumer products. Direct overlap with Polyamyna's MicroDome offering and a comparable OEM licensing business model.
• Sciessent (formerly Agion Technologies): US-based antimicrobial additive company (Agion silver-ion, Sciessent odor-control technologies) supplying polymer, textile, and coating manufacturers. Closest US-based direct peer to MicroDome with established FDA/EPA regulatory dossiers and OEM relationships.
• Steri-7 (Bio Technics): UK-based developer of residual antimicrobial surface disinfectants and coatings for healthcare, food processing, and consumer applications. Closest direct competitor in the residual-effect coating category overlapping with Keep Klear's value proposition.

Emerging players

• Entasis Therapeutics (an Innoviva company): Clinical-stage antibiotic developer (acquired by Innoviva in 2022) focused on serious drug-resistant infections, including ESKAPE pathogens. Most directly comparable peer for Polyamyna's PRP-2019 adjuvant antibiotic program, with a more advanced clinical stage and larger backing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/polyamyna
• YouTubeyoutube.com/@polyamyna839
• LinkedInin.linkedin.com/company/polyamyna-nanotech

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polyamyna